Dendreon Falls as Provenge Sales Miss Analysts’ Estimates
This article is for subscribers only.
Dendreon Corp., maker of the prostate cancer drug Provenge, fell the most in nine months after the company failed to meet analysts’ revenue estimates.
Dendreon dropped 15 percent to $4.03 at 4 p.m. New York time, its biggest decline since July 31. The stock has fallen 55 percent in the past 12 months.